Syndax Pharmaceuticals, Inc. Common Stock SNDX
i
Market dataready · fetched 2026-11-13T02:55:33.219Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:28:52.475967503Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T02:55:32.219824+00:00
Syndax Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 9.07 | 79.6% | 5.8% | |||
| 45Δ | 9.55 | 137.5% | 10.1% | 9.21 | 78.7% | 5.2% |
| 50Δ | 9.37 | 153.6% | 9.8% | 9.35 | 77.9% | 4.6% |
| 55Δ | 9.18 | 169.7% | 9.5% | 9.48 | 77.0% | 3.9% |
| 60Δ | 8.98 | 186.2% | 9.2% | 9.62 | 76.1% | 3.3% |
| 65Δ | 8.58 | 212.1% | 8.7% | 9.76 | 75.2% | 2.7% |
| 70Δ | 8.17 | 238.1% | 8.1% | 9.90 | 74.4% | 2.0% |
| 75Δ | 7.71 | 254.1% | 6.9% | 10.10 | 75.9% | 1.5% |
| 80Δ | 7.21 | 262.9% | 5.3% | 10.47 | 84.0% | 1.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.07
- IV
- 79.6%
- B/E move
- 5.8%
45Δ
- Pseudo strike
- 9.55
- IV
- 137.5%
- B/E move
- 10.1%
- Pseudo strike
- 9.21
- IV
- 78.7%
- B/E move
- 5.2%
50Δ
- Pseudo strike
- 9.37
- IV
- 153.6%
- B/E move
- 9.8%
- Pseudo strike
- 9.35
- IV
- 77.9%
- B/E move
- 4.6%
55Δ
- Pseudo strike
- 9.18
- IV
- 169.7%
- B/E move
- 9.5%
- Pseudo strike
- 9.48
- IV
- 77.0%
- B/E move
- 3.9%
60Δ
- Pseudo strike
- 8.98
- IV
- 186.2%
- B/E move
- 9.2%
- Pseudo strike
- 9.62
- IV
- 76.1%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 8.58
- IV
- 212.1%
- B/E move
- 8.7%
- Pseudo strike
- 9.76
- IV
- 75.2%
- B/E move
- 2.7%
70Δ
- Pseudo strike
- 8.17
- IV
- 238.1%
- B/E move
- 8.1%
- Pseudo strike
- 9.90
- IV
- 74.4%
- B/E move
- 2.0%
75Δ
- Pseudo strike
- 7.71
- IV
- 254.1%
- B/E move
- 6.9%
- Pseudo strike
- 10.10
- IV
- 75.9%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 7.21
- IV
- 262.9%
- B/E move
- 5.3%
- Pseudo strike
- 10.47
- IV
- 84.0%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.66% | |
| 75.74% | |
| 85.40% | |
| 75.47% | |
| 74.86% | |
| 83.90% | |
| 76.58% | |
| 64.83% | |
| 66.60% | |
| 71.71% |
Biotechnology
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR)…
More →SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to…
More →SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic…
More →SRRK
Description unavailable
More →SRZN
Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform, which is designed to…
More →STOK
Description unavailable
More →